Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...
In-silico trials (ISTs) are rapidly emerging as an integral part of pharmaceutical R&D and regulatory evaluation. These ...
The 33rd Vietnam International Medical and Pharmaceutical Exhibition (Vietnam Medi-Pharm 2025) and the International ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback